The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 237 of the 241 references it cites were found in a registry or an index.
Abstract
Objective: To develop clinical practice guidelines for the management of patients with primary aldosteronism. Participants: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee of the Endocrine Society, six additional experts, a methodologist, and a medical writer. The guideline was cosponsored by American Heart Association, American Association of Endocrine Surgeons, European Society of Endocrinology, European Society of Hypertension, International Association of Endocrine Surgeons, International Society of Endocrinology, International Society of Hypertension, Japan Endocrine Society, and The Japanese Society of Hypertension. The Task Force received no corporate funding or remuneration. Evidence: We searched for systematic reviews and primary studies to formulate the key treatment and prevention recommendations. We used the Grading of Recommendations, Assessment, Development, and Evaluation group criteria to describe both the quality of evidence and the strength of recommendations. We used “recommend” for strong recommendations and “suggest” for weak recommendations. Consensus Process: We achieved consensus by collecting the best available evidence and conducting one group meeting, several conference calls, and multiple e-mail communications. With the help of a medical writer, the Endocrine Society's Clinical Guidelines Subcommittee, Clinical Affairs Core Committee, and Council successfully reviewed the drafts prepared by the Task Force. We placed the version approved by the Clinical Guidelines Subcommittee and Clinical Affairs Core Committee on the Endocrine Society's website for comments by members. At each stage of review, the Task Force received written comments and incorporated necessary changes. Conclusions: For high-risk groups of hypertensive patients and those with hypokalemia, we recommend case detection of primary aldosteronism by determining the aldosterone-renin ratio under standard conditions and recommend that a commonly used confirmatory test should confirm/exclude the condition. We recommend that all patients with primary aldosteronism undergo adrenal computed tomography as the initial study in subtype testing and to exclude adrenocortical carcinoma. We recommend that an experienced radiologist should establish/exclude unilateral primary aldosteronism using bilateral adrenal venous sampling, and if confirmed, this should optimally be treated by laparoscopic adrenalectomy. We recommend that patients with bilateral adrenal hyperplasia or those unsuitable for surgery should be treated primarily with a mineralocorticoid receptor antagonist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Algorithm for the detection, confirmation, subtype testing, and treatment of PA. a We recommend unilateral laparoscopic adrenalectomy for patients with documented unilateral PA (ie, APA or UAH) (1 ⎪ QQQE ). If a patient is unable or unwilling to undergo surgery, we recommend medical treatment including a MR antagonist (1 ⎪ QQQE ). If an ARR-positive patient is unwilling or unable to undergo further investigations, we similarly recommend medical treatment including an MR antagonist (1 ⎪ QQEE ). b Instead of proceeding directly to subtype classification, we recommend that patients with a positive ARR undergo one or more confirmatory tests to definitively confirm or exclude the diagnosis (1 ⎪ QQEE ). However, in the setting of spontaneous hypokalemia, undetectable renin, and PAC > 20 ng/dL (550 pmol/L), we suggest that there may be no need for further confirmatory testing (2 ⎪ QEEE ). c We recommend that when surgical treatment is feasible and desired by the patient, an experienced radiologist should use AVS to make the distinction between unilateral and bilateral adrenal disease (1 ⎪ QQQE ). Younger patients ( < age 35) with spontaneous hypokalemia, marked aldosterone excess, and unilateral adrenal lesions with radiological features consistent with a cortical adenoma on adrenal CT scan may not need AVS before proceeding to unilateral adrenalectomy (2 ⎪ QEEE ). [Adapted from J. W. Funder et al: Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab . 2008;93:3266-3281 (3), with permission. © Endocrine Society.]](https://figures.cochat.ai/paper-figures/aaade82f5c4b425bbdee69e74321806d/the-management-of-primary-aldosteronism-case-detection-diagnosis-and-treatment-figure-1.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most common types of secondary hypertension in adults are renal parenchymal disease, renovascular hypertension, primary aldosteronism, chronic sleep apnea, and substance/drug-induced.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A specific cause of secondary hypertension can be identified in 5%-10% of hypertensive patients (Table 11).”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypokalemia, which reduces aldosterone secretion, should be corrected with oral K+ supplements before testing.”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [289]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with unilateral disease (50%; aldosterone-producing adenoma or, much less frequently, unilateral hyperplasia) respond to unilateral laparoscopic adrenalectomy with complete cure (≈50%) or improvement (≈50%) in BP control.”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [289]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation group, an international group with expertise in the development and implementation of evidence-based guidelines (2).”
MethodNational High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) · PEDIATRICS · doi:10.1542/peds.114.2.s2.555 · Cited by 6,938
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
(2003) · Journal of Hypertension · doi:10.1097/00004872-200311000-00002 · Cited by 2,672
Funder, J. W., Carey, R. M., Fardella, C., Gomez-Sanchez, C. E., Mantero, F., Stowasser, M., Young, W. F., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0104 · Cited by 1,554 · cited 3×
“The recommendations and suggestions made by the Task Force were subject to extensive consultation before being published in the Journal of Clinical Endocrinology and Metabolism in 2008 (3).”
MethodSelf-citationEvidence for an increased rate of cardiovascular events in patients with primary aldosteronism
Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., & Mourad, J.-J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.015 · Cited by 1,547 · cited 2×
“Several outcome studies also have provided evidence that PA patients are particularly at risk of cardiovascular/ renal complications, including arrhythmias, myocardial infarction, strokes, chronic kidney disease, and death, compared with age-, sex-, and BP-matched essential hypertensives (30, 33, 156).”
BackgroundResultA prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients
Rossi, G. P., Bernini, G., Caliumi, C., Desideri, G., Fabris, B., Ferri, C., Ganzaroli, C., Giacchetti, G., Letizia, C., Maccario, M., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.059 · Cited by 1,467 · cited 2×
“However, some groups have suggested that when clinicians administer a bolus injection of cosyntropin and sample the adrenal veins simultaneously, cosyntropin does not improve the diagnostic accuracy of AVS, and, in fact, cosyntropin may increase secretion from the nonadenomatous gland to a greater degree than from the…”
BackgroundSelf-citation
Research works printed but not linked: 3
- 15. Tucker RM, Labarthe DR. Frequency of surgical treatment for hypertensioninadultsattheMayoClinicfrom1973through1975. Mayo Clin Proc . 1977;52:549-545.
- 133. FardellaCE,PintoM,MossoL,Gómez-SánchezC,JalilJ,Montero J. Genetic study of patients with dexamethasone-suppressible aldosteronismwithoutthechimericCYP11B1/CYP11B2gene. J Clin Endocrinol Metab . 2001;86:4805-4807.
- 169. Jacobsen NE, Campbell JB, Hobart MG. Laparoscopic versus openadrenalectomyforsurgicaladrenaldisease. CanJUrol . 2003; 10:1995-1999.
Cited by
Items 401–500 of 1,002
A Political Theory of Progressive Income Taxation
Cukierman, A., & Meltzer, A. H. (2018) · KiltHub Repository · doi:10.1184/r1/6703181 · Cited by 33
Hu, J., Cai, X., Zhu, Q., Heizhati, M., Wen, W., Luo, Q., Hong, J., Dang, Y., Yang, W., & Li, N. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s408722 · Cited by 32
“Hormonal tests were conducted according to current guidelines and prior studies conducted at our center.(32,33) PAC was measured by radioimmunoassay (DSL-8600 ACTIVE Aldosterone Coated Tube Radioimmunoassay Kit; Diagnostic Systems Laboratories, Webster, TX), with participants instructed to refrain from caffeine, alcoh…”
MethodCharacterizing the Origins of Primary Aldosteronism
Brown, J. M., Honzel, B., Tsai, L. C., Milks, J., Neibuhr, Y., Newman, A. J., Cherney, M. D., Stouffer, D. G., Auchus, R. J., & Vaidya, A. (2024) · Hypertension · doi:10.1161/hypertensionaha.124.24153 · Cited by 34
Vorselaars, W. M. C. M., van Beek, D., Postma, E. L., Spiering, W., Rinkes, I. H. M. B., Valk, G. D., Vriens, M. R., Zarnegar, R., Drake, F. T., Duh, Q. Y., et al. (2019) · Surgery · doi:10.1016/j.surg.2019.01.031 · Cited by 35
“064 EPRA 152 (40) 48 (43) 75 (41) 29 (34) ELRA 52 (14) 12 (11) 21 (12) 19 (22) LTA 176 (46) 52 (46) 87 (48) 37 (44) Robot assisted 14 (4) 8 (7) 5 (3) 1 (1) .”
Athimulam, S., Lazik, N., & Bancos, I. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.08.003 · Cited by 35
Guo, Z., Nanba, K., Udager, A. M., McWhinney, B. C., Ungerer, J. P. J., Wolley, M. J., Thuzar, M., Gordon, R. D., Rainey, W. E., & Stowasser, M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa367 · Cited by 34
Self-citationOutcomes in unilateral primary aldosteronism after surgical or medical therapy
Puar, T. H. K., Loh, L. M., Loh, W. J., Lim, D. S. T., Zhang, M., Tan, P. T., Lee, L. M. Y., Swee, D. S., Khoo, J. J. C., Tay, D., et al. (2020) · Clinical Endocrinology · doi:10.1111/cen.14351 · Cited by 33
Adrenal Venous Sampling in Young Patients with Primary Aldosteronism. Extravagance or Irreplaceable?
Gkaniatsa, E., Sakinis, A., Palmér, M., Muth, A., Trimpou, P., & Ragnarsson, Ó. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab047 · Cited by 33
The Effect of Antihypertensive Medications on Testing for Primary Aldosteronism
Jędrusik, P., Symonides, B., Lewandowski, J., & Gaciong, Z. A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.684111 · Cited by 32
“…that high cut-off values of ARR above 100 (expressed in ng/dL over ng/mL/h) were identified in 15 among 90 patients with poorly controlled hypertension without discontinuation of their multidrug therapy regimen, but the performance of lower cut-off values was not provided (Gallay et al., 2001).”
BackgroundAriens, J., Horvath, A. R., Yang, J., & Choy, K. W. (2022) · Endocrine · doi:10.1007/s12020-022-03084-x · Cited by 32
Characterization of Aldosterone-producing Cell Cluster (APCC) at Single-cell Resolution
Iwahashi, N., Umakoshi, H., Seki, T., Gómez-Sánchez, C. E., Mukai, K., Suematsu, M., Umezawa, Y., Oya, M., Kosaka, T., Seki, M., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac394 · Cited by 33
Clinical utility of laboratory developed mass spectrometry assays for steroid hormone testing
French, D. (2023) · Journal of Mass Spectrometry and Advances in the Clinical Lab · doi:10.1016/j.jmsacl.2023.01.006 · Cited by 33
Aldosterone to Renin Ratio as Screening Tool in Primary Aldosteronism
Schilbach, K., Junnila, R. K., & Bidlingmaier, M. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0672-0836 · Cited by 38
“Consequently, extending search for PA to normokalemic patients had significant impact on prevalence of the disease: While prevalence of PA was believed to be less than 1 % 20 years ago, currently it is estimated that approximately 10 % of all cases of hypertension are caused by PA [2].”
BackgroundInfluentialYang, Y., Xiao, M., Song, Y., Tang, Y., Luo, T., Yang, S., He, W., Cheng, Q., Ma, L., Zhang, Y., et al. (2019) · Endocrine · doi:10.1007/s12020-019-02022-8 · Cited by 38
Lee, S. H., Kim, J. W., Yoon, H., Koh, J.-M., Shin, C. S., Kim, J. H., & Kim, J. H. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.901 · Cited by 32
“Primary aldosteronism (PA) is the most common cause of secondary hypertension (HTN), affecting 5% to 10% of hypertensive patients [1], increasing various cardiovascular complications [2-4].”
BackgroundMethodInfluentialBongarzone, S., Basagni, F., Sementa, T., Singh, N., Gakpetor, C., Faugeras, V., Bordoloi, J., & Gee, A. D. (2019) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2018.11.002 · Cited by 31
Ha, J., Park, J. H., Kim, K. J., Kim, J. H., Jung, K. Y., Lee, J., Choi, J. H., Lee, S. H., Hong, N., Lim, J. S., et al. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1789 · Cited by 32
“In patients aged > 65 years, renin can be lowered more than aldosterone by age alone, leading to false-positive ARR results [25].”
BackgroundMethodInfluentialGoupil, R., Desbiens, L., Merabtine, A., Agharazii, M., Madore, F., Vaidya, A., Leung, A. A. C., Kline, G. A., Shaw, J. L. V., Ramsay, T., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.073507 · Cited by 36
Inoue, K., Yamazaki, Y., Kitamoto, T., Hirose, R., Saito, J., Omura, M., Sasano, H., & Nishikawa, T. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00738 · Cited by 31
Wang, T., Lee, Y., Chang, S., Tung, Y., Yeh, C., Lin, Y., Pan, C., Hsu, C., Huang, C., Wu, C., et al. (2019) · PubMed Central · doi:10.6515/acs.201905_35(3).20190415a · Cited by 33
Age‐ and sex‐specific reference ranges are needed for the aldosterone/renin ratio
Solanki, P., Gwini, S. M., Doery, J. C. G., Choy, K. W., Shen, J., Young, M. J., Fuller, P. J., & Yang, J. (2020) · Clinical Endocrinology · doi:10.1111/cen.14199 · Cited by 31
Moraes, A. B., de Paula, M. P., Paranhos‐Neto, F. D. P., Cavalari, E. M. R., de Morais, F. F. C., Curi, D., Lima, L. F. C., de Mendonça, L. M. C., Farias, M. L. F., Madeira, M., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa263 · Cited by 32
Kim, K. J., Hong, N., Yu, M. H., Lee, H., Lee, S., Lim, J. S., & Rhee, Y. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.16909 · Cited by 31
“Patients with PA were subdivided into 2 groups based on the treatment strategy for PA that they received, as follows: (1) those who underwent ADX (ADX group) and (2) those who were prescribed MRA for >6 months without undergoing any ADX during follow-up (MRA group).”
MethodCeolotto, G., Antonelli, G., Caroccia, B., Battistel, M., Barbiero, G., Plebani, M., & Rossi, G. P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10204755 · Cited by 31
“Consecutive hypertensive patients with biochemically confirmed PA, who wished to pursue surgical cure, were prospectively recruited for the AVS study at University of Padua, an ESH Center of Excellence, if they had no contraindications to surgery and/or general anesthesia following current guidelines [1,2].”
The Th17/Treg imbalance in patients with primary hyperaldosteronism and resistant hypertension
Imiela, A. M., Mikolajczyk, T. P., Siedliński, M., Dobrowolski, P., Konior, A., Wróbel, A., Biernat‐Kałuża, E., Januszewicz, M., Guzik, B., Guzik, T. J., et al. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16171 · Cited by 31
Heinrich, D. A., Quinkler, M. O., Adolf, C., Handgriff, L., Müller, L., Schneider, H., Sturm, L., Kunzel, H. E., Seidensticker, M., Deniz, S., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-0541 · Cited by 32
Self-citationKatsuragawa, S., Goto, A., Shinoda, S., Inoue, K., Nakai, K., Saito, J., Nishikawa, T., & Tsurutani, Y. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.21096 · Cited by 34
Primary Aldosteronism: A Pragmatic Approach to Diagnosis and Management
Dogra, P., Bancos, I., & Young, W. F. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.04.023 · Cited by 33
Self-citationHannich, M. J., Wallaschofski, H., Nauck, M. A., Reincke, M., Adolf, C., Völzke, H., Rettig, R., & Hannemann, A. (2018) · International Journal of Endocrinology · doi:10.1155/2018/4128174 · Cited by 31
Self-citationPrimary aldosteronism subtype discordance between computed tomography and adrenal venous sampling
Aono, D., Kometani, M., Karashima, S., Usukura, M., Gondo, Y., Hashimoto, A., Demura, M., Furukawa, K., Takeda, Y., Kawashiri, M., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0310-y · Cited by 33
“Although younger patients (<age 35 years) with hypokalemia, marked aldosterone excess, and unilateral adrenal lesions on adrenal CT may not need AVS before surgery [13], relying on CT alone can generally lead to misdiagnoses of the PA subtype.”
BackgroundChang, Y., Tsai, C., Peng, S., Chen, Z., Chang, C., Lee, B., Liao, C., Pan, C., Chen, Y., Lin, L., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15679 · Cited by 31
“The diagnosis of APA was confirmed according to the modified 4-corner criteria after adrenalectomy,28,29 which were (1) evidence of excess aldosterone production according to an ARR >35, TAIPAI score >60%,30 and seated post-saline loading PAC >16 ng/dL or urine aldosterone >12 μg/24 hours31; (2) evidence of adenoma on…”
MethodPuar, T. H. K., Cheong, C. K., Foo, R., Saffari, S. E., Tu, T. M., Chee, M. R., Zhang, M., Ng, K. S., Wong, K. M., Wong, A. S. Y., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.916744 · Cited by 33
Yin, X., Ai, K., Luo, J., Liu, W., Ma, X., Zhou, L., Xiang, X., Su, X., Wang, Y., & Li, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1291775 · Cited by 32
Inoue, K., Naito, T., Fuji, R., Sonehara, K., Yamamoto, K., Baba, R., Kodama, T., Otagaki, Y., Okada, A., Itcho, K., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.034180 · Cited by 32
“…between East Asian and European populations such as sodium intake levels and clinical guidelines for PA (including screening procedures and pharmacological therapy 1,11,12 ), the potential heterogeneity in the cardiovascular burden of PA across populations should be the subject of future research.”
Zhou, J., Zhang, D., Li, W., Zhou, L., Xu, H., Zheng, S., & Wang, C. (2019) · Endocrine · doi:10.1007/s12020-019-01992-z · Cited by 32
Adrenal venous sampling in patients with ACTH-independent hypercortisolism
Papakokkinou, E., Jakobsson, H., Sakinis, A., Muth, A., Wängberg, B., Ehn, O., Johannsson, G., & Ragnarsson, Ó. (2019) · Endocrine · doi:10.1007/s12020-019-02038-0 · Cited by 31
Sivarajah, M., Beninato, T. M., & Fahey, T. J. (2019) · Surgery · doi:10.1016/j.surg.2019.05.087 · Cited by 31
Lee, J., Kang, B., Ha, J., Kim, M., Choi, B., Hong, T. H., Kang, M. I., & Lim, D. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00591-8 · Cited by 34
Monogenic forms of low-renin hypertension: clinical and molecular insights
Khandelwal, P., & Deinum, J. (2021) · Pediatric Nephrology · doi:10.1007/s00467-021-05246-x · Cited by 34
Castro, M. A., Paja, M., Boillos, M. G., Peris, B. P., Corrales, E. P., Cano, A. M. G., Ramírez, P. A. P., Rojas‐Marcos, P. M., Ruiz-Sánchez, J. G., Delgado, A. V., et al. (2022) · Endocrine · doi:10.1007/s12020-022-03029-4 · Cited by 30
Secondary diabetes mellitus due to primary aldosteronism
Moustaki, M., Paschou, S. Α., Vakali, E., & Vryonidou, A. (2022) · Endocrine · doi:10.1007/s12020-022-03168-8 · Cited by 31
New advances in endocrine hypertension: from genes to biomarkers
Fernandes-Rosa, F. L., Boulkroun, S., Fedlaoui, B., Hureaux, M., Travers, S. A. A., Drossart, T., Favier, J., & Zennaro, M. (2023) · Kidney International · doi:10.1016/j.kint.2022.12.021 · Cited by 32
Chazova, I. E., Михайловна, Ч. Н., Blinova, N. V., Belaya, Z. E., Danilov, N. M., Elfimova, E. M., Litvin, A. Y., Rozhinskaya, L. Y., Sviridenko, N. Y., Швецов, М. Ю., et al. (2023) · Eurasian heart journal · doi:10.38109/2225-1685-2023-1-6-65 · Cited by 35
Schneider, H., Sarkis, A., Sturm, L., Britz, V., Lechner, A., Potzel, A. L., Müller, L., Heinrich, D. A., Kunzel, H. E., Nowotny, H. F., et al. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13618 · Cited by 32
“A total of 44 patients with PA were recruited from the Munich center of the German Conn’s Registry after having been diagnosed with PA based on the Endocrine Society Clinical Practice Guidelines [15].”
MethodSelf-citationCastro, M. A., Paja, M., Peris, B. P., Boillos, M. G., Corrales, E. P., Cano, A. M. G., Ramírez, P. A. P., Rojas‐Marcos, P. M., Ruiz-Sánchez, J. G., Vicente, A., et al. (2023) · Endocrine Connections · doi:10.1530/ec-23-0043 · Cited by 32
Evaluation of a Best-Practice Advisory for Primary Aldosteronism Screening
Charoensri, S., Bashaw, L., Dehmlow, C. L. R., Ellies, T., Wyckoff, J., & Turcu, A. F. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.7389 · Cited by 31
Pathogenesis of Familial Hyperaldosteronism Type II: New Concepts Involving Anion Channels
Stowasser, M., Wolley, M. J., Wu, A., Gordon, R. D., Schewe, J., Stölting, G., & Scholl, U. I. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0934-y · Cited by 34
Self-citationBurrello, J., Gai, C., Tetti, M., Lopatina, T., Deregibus, M. C., Veglio, F., Mulatero, P., Camussi, G., & Monticone, S. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.12944 · Cited by 32
Primary aldosteronism as a public health issue
Funder, J. W. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30272-8 · Cited by 30
Self-citationDeinum, J., Prejbisz, A., Lenders, J. W. M., & van der Wilt, G. J. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09294 · Cited by 30
Urine steroid metabolomics as a diagnostic tool in primary aldosteronism
Prete, A., Lang, K., Pavlov, D., Rhayem, Y., Sitch, A. J., Franke, A. S., Gilligan, L. C., Shackleton, C. H. L., Hahner, S., Quinkler, M. O., et al. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106445 · Cited by 30
“The diagnosis and subtype differentiation of PA was confirmed according to local protocols in accordance with Endocrine Society guidelines [1].”
BackgroundMethodInfluentialSelf-citationFarah, M. H., Hegazi, M., Firwana, M., Abusalih, M. E., Saadi, S. M., Al-Kordi, M., Elsheikh, A. M., Wang, Z., Hassett, L. C., Bancos, I., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf290 · Cited by 29
Self-citationZhang, Y., Niu, W., Zheng, F., Zhang, H., Zhou, W., Shen, Z., Xu, J., Tang, X., Zhang, J., Gao, P., et al. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001488 · Cited by 29
“experienced radiologist should use AVS to distinguish between unilateral and bilateral adrenal disease [5].”
MethodBurrello, J., Amongero, M., Buffolo, F., Sconfienza, E., Forestiero, V., Burrello, A., Adolf, C., Handgriff, L., Reincke, M., Veglio, F., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa974 · Cited by 29
Self-citationOverview of Monogenic Forms of Hypertension Combined With Hypokalemia
Lu, Y., Fan, P. T., Zhang, D., Zhang, Y., Meng, X., Zhang, Q.-Y., Zhao, L. Y., Yang, K., & Zhou, X. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2020.543309 · Cited by 32
Adolf, C., Görge, V., Heinrich, D. A., Hoster, E., Schneider, H., Handgriff, L., Kunzel, H. E., Sturm, L., Beuschlein, F., & Reincke, M. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.16440 · Cited by 30
Self-citationTherapeutic Outcomes with Surgical and Medical Management of Primary Aldosteronism
Wachtel, H., & Fraker, D. L. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01516-0 · Cited by 31
A multidisciplinary approach to the management of adrenal incidentaloma
Voltan, G., Boscaro, M., Armanini, D., Scaroni, C. M., & Ceccato, F. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1948327 · Cited by 30
“angiotensin receptor blockers, and beta-blockers at least 2 weeks before [60].”
BackgroundMethodВладимировна, А. А., Анатольевна, С. О., Blinova, N. V., Danilov, N. M., Elfimova, E. M., Кislyak, O. A., Litvin, A. Y., Ощепкова, Е. В., Fomin, V. V., Михайловна, Ч. Н., et al. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.09.201007 · Cited by 30
Mendiratta‐Lala, M., Avram, A. M., Turcu, A. F., & Dunnick, N. R. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.04.009 · Cited by 31
“Thus, AVS is often used in the subclassification of patients with primary aldosteronism.(7,8) Although CT and MRI are valuable in localizing hormone-producing tumors, incidental findings are often detected in organs other than the one for which the examina-”
MethodNainani, A., Yang, J., Peters, S., & Russell, G. M. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061671 · Cited by 29
Yoshida, Y., Fujiki, R., Kinoshita, M., Sada, K., Miyamoto, S., Ozeki, Y., Mori, Y., Matsuda, N., Noguchi, T., Nakama, H., et al. (2022) · Hypertension Research · doi:10.1038/s41440-022-01045-5 · Cited by 30
Self-citationExclusion Tests in Unilateral Primary Aldosteronism (ExcluPA) Study
Zhu, R., Shagjaa, T., Rossitto, G., Caroccia, B., Seccia, T. M., Gregori, D., & Rossi, G. P. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac654 · Cited by 30
Vascular and hormonal interactions in the adrenal gland
Abdellatif, A. B., Fernandes-Rosa, F. L., Boulkroun, S., & Zennaro, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.995228 · Cited by 31
Fallo, F., Castellano, I., Gómez-Sánchez, C. E., Rhayem, Y., Pilon, C., Vicennati, V., Santini, D., Maffeis, V., Fassina, A., Mulatero, P., et al. (2017) · Endocrine · doi:10.1007/s12020-017-1295-4 · Cited by 29
Self-citationPrimary Aldosteronism and Obstructive Sleep Apnea: Casual Association or Pathophysiological Link?
Pecori, A., Buffolo, F., Pieroni, J., Forestiero, V., Sconfienza, E., Veglio, F., Mulatero, P., & Monticone, S. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1133-7255 · Cited by 30
“Studies performed in the last years suggest that PA is frequent in patients with OSA [5, 6] and, on the basis of these evidences, the 2016 Endocrine Society Guideline recommends to screen for PA all patients with hypertension and OSA [7].”
BackgroundMurck, H., Adolf, C., Schneider, A., Schlageter, L., Heinrich, D. A., Ritzel, K., Sturm, L., Quinkler, M. O., Beuschlein, F., Reincke, M., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.02.064 · Cited by 30
Self-citationMidan, H. M., Helal, G. K., Abulsoud, A. I., Elshaer, S. S., El-Husseiny, A. A., Fathi, D., Abdelmaksoud, N. M., Mageed, S. S. A., Elballal, M. S., Zaki, M. B., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154690 · Cited by 28
Murakami, M., Naruse, M., Kobayashi, H. H., Parasiliti‐Caprino, M., Bioletto, F., Brüdgam, D., Stüfchen, I., Reincke, M., St‐Jean, M., Kraljević, I., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf117 · Cited by 31
Self-citationWang, T. S., Kline, G. A., Yen, T. W. F., Yin, Z., Liu, Y., Rilling, W. S., So, B., Findling, J. W., Evans, D. B., & Pasieka, J. L. (2017) · World Journal of Surgery · doi:10.1007/s00268-017-4327-6 · Cited by 28
The spectrum of low-renin hypertension
Buffolo, F., Monticone, S., Pecori, A., Pieroni, J., Losano, I., Cavaglià, G., Tetti, M., Veglio, F., & Mulatero, P. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101399 · Cited by 34
Liu, B., Hu, J., Song, Y., He, W., Cheng, Q., Wang, Z., Feng, Z., Du, Z., Xu, Z., Yang, J., et al. (2020) · Endocrine Practice · doi:10.1016/j.eprac.2020.10.016 · Cited by 28
Tsai, C., Chen, Y., Pan, C., Lin, Y.-T., Lee, P.-C., Chiu, Y., Liao, C., Chen, Z., Chang, C., Chang, Y., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.646933 · Cited by 28
Rubinstein, G., Oßwald, A., Braun, L., Vogel, F., Kroiß, M., Pilz, S., Deniz, S., Aigner, L. I., Knösel, T., Bertherat, J. Y., et al. (2022) · Endocrine · doi:10.1007/s12020-022-03020-z · Cited by 29
“Another approach is adrenal venous sampling (AVS) which is commonly used in the diagnostic work-up for primary aldosteronism [18].”
BackgroundSelf-citationSex differences in hypertension. Do we need a sex-specific guideline?
Cífková, R., & Strilchuk, L. M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.960336 · Cited by 33
Zhou, Y., Liu, Q., Wang, X., Wan, J., Liu, S., Luo, T., He, P., Hou, J., Jing, P., Wang, D., et al. (2022) · American Journal of Hypertension · doi:10.1093/ajh/hpac105 · Cited by 28
Mizoguchi, R., Karashima, S., Miyajima, Y., Ogura, K., Kometani, M., Aono, D., Konishi, S., Demura, M., Tsujiguchi, H., Hara, A., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01334-7 · Cited by 29
Yang, S., Du, Z., Zhang, X., Zhen, Q., Shu, X., Yang, J. J., Song, Y., Yang, Y., Li, Q., Hu, J., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.38209 · Cited by 30
Tsiavos, V., Markou, Α., Papanastasiou, L., Kounadi, T., Androulakis, I. I., Voulgaris, N., Zachaki, A., Kassi, E. N., Kaltsas, G., Chrousos, G. P., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0003 · Cited by 30
Karashima, S., Kometani, M., Tsujiguchi, H., Asakura, H., Nakano, S., Usukura, M., Mori, S., Ohe, M., Sawamura, T., Okuda, R., et al. (2017) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2017.1339072 · Cited by 31
“Several endocrinology guidelines for hypertension have also recommended patients with higher blood pressure be confirmed or excluded from PA (20, 21).”
BackgroundUpdate in diagnosis and management of primary aldosteronism
Dick, S. M., Queiroz, M., Bernardi, B. L., Dall’Agnol, A., Brondani, L. D. A., & Silveiro, S. P. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2017-0217 · Cited by 33
Kline, G. A., Darras, P., Leung, A. A. C., So, B., Chin, A., & Holmes, D. T. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001905 · Cited by 28
Chee, N. Y. N., Abdul‐Wahab, A., Libianto, R., Gwini, S. M., Doery, J. C. G., Choy, K. W., Chong, W., Lau, K. K., Lam, Q. T., MacIsaac, R. J., et al. (2020) · Clinical Endocrinology · doi:10.1111/cen.14220 · Cited by 28
“Catheterization during adrenal vein sampling for primary aldosteronism: failure to use (1-24) ACTH may increase apparent failure rate.”
BackgroundCardenas, S. M. C., & Santhanam, P. (2020) · Endocrine · doi:10.1007/s12020-020-02474-3 · Cited by 28
Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment
Hundemer, G. L. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1185-x · Cited by 27
Aldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?
Mazzieri, A., Timio, F., Patera, F., Trepiccione, F., Bonomini, M., & Reboldi, G. (2024) · Kidney & Blood Pressure Research · doi:10.1159/000542621 · Cited by 29
“International guidelines consistently recommend S-MRAs, such as spironolactone and eplerenone, for treating primary aldosteronism [50], resistant hypertension (rHTN) [51], and heart failure [52].”
The prevalence of primary aldosteronism and evolving approaches for treatment
Yozamp, N. S., & Vaidya, A. (2019) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2019.07.001 · Cited by 32
Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS
Fuß, C. T., Brohm, K., Kurlbaum, M., Hannemann, A., Kendl, S., Faßnacht, M., Deutschbein, T., Hahner, S., & Kroiß, M. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0073 · Cited by 30
Jing, Y., Liao, K., Li, R., Yang, S., Song, Y., He, W., Wang, K., Yang, J., Li, Q., & Hu, J. (2021) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/14703203211003781 · Cited by 30
“A final diagnosis of APA was considered proven, providing that all the following conditions were satisfied: (1) histologic demonstration of adenoma, (2) nor-Malization of hypokalaemia if present, (3) cure or improvement of hypertension and (4) normalisation of ARR and suppressibility of aldosterone levels less than 5…”
MethodHuang, W., Chen, Y., Lin, Y., & Chueh, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.644260 · Cited by 30
Cohen, D. L., Wachtel, H., Vaidya, A., Hundemer, G. L., Tezuka, Y., Davio, A. C., Turcu, A. F., & Cohen, J. B. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.21474 · Cited by 30
“6,16 Confirmatory testing for PA was performed as clinically indicated.”
MethodTagawa, M., Ghosn, M., Wachtel, H., Fraker, D. L., Townsend, R. R., Trerotola, S. O., & Cohen, D. L. (2017) · Journal of Human Hypertension · doi:10.1038/jhh.2016.92 · Cited by 27
Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism
Park, K. S., Kim, J. H., Yang, Y., Hong, A. R., Lee, D., Moon, M. K., Choi, S. H., Shin, C. S., Kim, S. W., & Kim, S. Y. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej16-0530 · Cited by 27
Perioperative Management of Endocrine Active Adrenal Tumors
Schreiner, F., Anand, G., & Beuschlein, F. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0654-5251 · Cited by 31
“[40] Based on an international retrospective analysis of 705 patients from 12 different centers (The Primary Aldosteronism Surgical Outcome study, PASO), standardized criteria for postoperative outcome with regard to clinical and biochemical response were defined.”
BackgroundMethodInfluentialTratamiento del hiperaldosteronismo primario
Castro, M. A. (2020) · Medicina Clínica · doi:10.1016/j.medcli.2020.04.029 · Cited by 29
Novel Approach to Establishing an Aldosterone: Renin Ratio Cutoff for Primary Aldosteronism
Leung, A. A. C., Orton, D. J., Chin, A., Sadrzadeh, H. S. M., & Kline, G. A. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.08407 · Cited by 30
Primary Aldosteronism: At the Tipping Point
Funder, J. W. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1758 · Cited by 27
“Much of the present guideline (8) needs to be jettisoned, and radically reconstructed recommendations should be developed to guide clinicians treating hypertensive patients.”
BackgroundSelf-citationHuang, M., Li, J., Zhao, X., Fu, R., Li, X., & Jiang, W. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102791 · Cited by 28
Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women
Elhassan, Y., Hawley, J. M., Cussen, L., Abbara, A., Clarke, S. A., Kempegowda, P., Dhillon‐Smith, R. K., Thadani, P., Busby, M., Owusu‐Darkwah, L., et al. (2025) · Clinical Endocrinology · doi:10.1111/cen.15265 · Cited by 31
“Successful adrenal vein cannulation is confirmed using an adrenal:peripheral cortisol gradient > 2 at baseline and > 5 after ACTH stimulation [189].”
Volpe, C., Hamberger, B., Zedenius, J., & Juhlin, C. C. (2019) · Scandinavian Journal of Surgery · doi:10.1177/1457496918822622 · Cited by 26
“The PA diagnosis was established following the Endocrine Society guidelines (15).”
Method
Metadata
- Authors
- Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., & Young, W. F.
- Affiliations
- Hudson Institute of Medical Research (AU)
- University of Virginia Health System (US)
- University of Padua (IT)
- Mayo Clinic (US)
- Klinikum of the Ludwig-Maximilians-University of Munich (M.R.), 80366 München, Bavaria, Germany
- Oita University (JP)
- The University of Queensland (AU)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-05-01
- Volume
- 101
- Issue
- 5
- Pages
- 1889-1916
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2290633895
- Semantic Scholar
- 36716f26ebd3b8e468f352d9132208c41e5688c0
- Cited by
- 2,925
- References
- 241
- Citations by year
- 2026: 236 · 2025: 397 · 2024: 315 · 2023: 329 · 2022: 329 · 2021: 315 · 2020: 293 · 2019: 238 · 2018: 200 · 2017: 188 · 2016: 72
- FWCI
- 233.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- primary aldosteronism, case finding, aldosterone-renin ratio, adrenal computed tomography, adrenal vein sampling, laparoscopic adrenalectomy, bilateral adrenal hyperplasia, mineralocorticoid receptor antagonists, hypertension, hypokalemia
- MeSH terms
- Adrenal Glands, Adrenalectomy, Aldosterone, Mineralocorticoid Receptor Antagonists, Humans, Hyperaldosteronism, Renin, Evidence-Based Medicine, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.